◈ Nootpedia
Compact view
Research pass: medium Compound OPTIONAL-ADD LOW

7,8-Dihydroxyflavone

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD LOW

Strong rodent evidence for BDNF-pathway activation, neuroprotection, and TBI/depression models — but human data is essentially absent and oral bioavailability is poor (~5%). Speculative pick for Dylan's brain-protection thesis; 7,8-DHF prodrug R-13 may be the path forward.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    low — interesting speculative pick for MMA neuroprotection; gate on bloodwork + 23andMe + better source quality.

  • 30-50, executive maintenance
    OPTIONAL

    low — speculative cognitive booster.

  • 50+, mild cognitive decline
    OPTIONAL

    preclinical AD evidence is suggestive but not actionable; prefer evidence-based options first.

  • Anxiety-prone
    NEUTRAL

    possibly mildly anxiolytic via BDNF pathway; unclear.

  • High athletic load, tested status
    OPTIONAL

    possible neuroprotective relevance to contact sport.

  • Sleep-disordered
    NEUTRAL
  • Recovery-focused (post-injury, post-illness)
    OPTIONAL

    TBI rodent data is compelling; relevant if post-concussion.

  • Strength/anabolic-focused
    N
▸ Subjective experience (deep)
  • Reports vary widely. Most consistent themes: subtle mood elevation, mild improvement in mental clarity/focus over 1-2 weeks of daily use.
  • Some report nothing — likely the bioavailability problem.
  • Sublingual or liposomal forms anecdotally feel stronger (bypasses first-pass).
  • Not a "felt" nootropic like racetams or stimulants — operates on a slower timeline if it works at all.
▸ Tolerance + cycling deep dive
  • Tolerance: unknown — TrkB receptor downregulation theoretically possible with chronic agonism.
  • Recommended cycle: speculative — most users cycle as a precaution.
  • Reset protocol: 2-4 weeks off if cycling.
▸ Stacking deep dive

Synergistic with

  • Lion's mane (NGF/BDNF support via different pathway): theoretical complementary neurotrophic action.
  • Cerebrolysin (peptide-based BDNF/NGF mimetic): possibly additive but untested.
  • DHA (omega-3): supports membrane fluidity and TrkB signaling milieu.

Avoid stacking with

  • Active malignancy or strong family cancer history: skip until human safety data exists.
  • BDNF-modulating Rx (some antidepressants): theoretical additive — clinical relevance unknown.

Neutral / safe co-administration

  • Most cognitive enhancers; no known major interactions.
▸ Drug interactions deep dive
  • Glucuronidation pathway shared with many drugs/supplements — competition possible but clinically uncharacterized.
  • No CYP interactions documented.
▸ Pharmacogenomics
  • BDNF Val66Met (rs6265) polymorphism affects baseline BDNF release; theoretical differential response to TrkB agonism — unstudied.
  • 23andMe will report Val66Met; could inform decision after results land.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem powder Newmind / Nootropics Depot (when in stock) $30-60 / 5-10 g medium-high NDP has historically tested batches; Newmind variable
Capsules Various nootropic vendors $30-50 / 30-60 caps medium Verify dose accuracy
Prodrug R-13 / R7 Not commercially available — — Pharma-stage compounds; check trial registries
▸ Biomarkers to track (deep)
  • Baseline: Cognitive testing (Cambridge Brain Sciences, Quantified Mind, etc.), mood self-report, BDNF Val66Met genotype.
  • During use: Subjective cognitive output, mood, sleep quality. Serum BDNF is poorly correlated with brain BDNF — limited utility.
  • Post-cycle: Re-test cognitive baseline.
▸ Controversies / open debates Live debate
  • Whether oral 7,8-DHF actually achieves brain concentrations sufficient for TrkB activation in humans — likely no at standard doses; preclinical work mostly used IP injection.
  • Long-term safety of chronic TrkB agonism in humans — theoretical cancer/proliferation concerns vs expected neuroprotective benefits.
  • Sublingual vs oral bioavailability — anecdotal claims, no controlled data.
  • Whether prodrug forms (R-13) will actually reach market — Ye lab has been pursuing this for >10 years.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: OPTIONAL-ADD low. Compelling preclinical neuroprotective profile fits Dylan's MMA-protection thesis, but bioavailability problems + zero human data + cancer-signaling theoretical concerns keep it speculative.
▸ Open questions / gaps Open
  • Human PK study with oral 7,8-DHF (does plasma reach effective concentration?).
  • Brain penetration data in humans.
  • Long-term chronic safety, especially in healthy adults under 30.
  • Whether R-13 prodrug becomes commercially or trial-accessible.
  • Whether stacking with lion's mane / cerebrolysin produces measurable additive cognitive benefit.
▸ Sources (full, with our context)
Back to compact view